The risk of neoplasms in patients treated with cyclosporine A
References (18)
- et al.
Risk of cancer in renal-transplant recipients
Lancet
(1973) - et al.
Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers
Lancet
(1979) - et al.
Cyclosporin A immunosuppression, Epstein-Barr antibody, and lymphoma
Lancet
(1980) - et al.
Epstein-Barr virus-induced lymphoma in a cardiac transplant recipient
Am. J. Med.
(1984) - et al.
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy
Lancet
(1984) - et al.
Kaposi's sarcoma in recipients of renal transplants
Am. J. Med.
(1979) - et al.
Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs
Br. Med. J.
(1979) - et al.
Cancer and survival after cadaveric donor renal transplantation
Transplant. Proc.
(1979) - et al.
Development and incidence of cancer following cyclosporine therapy
Transplant. Proc.
(1986)
Cited by (125)
Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management
2018, Best Practice and Research: Clinical RheumatologyThe use of cyclosporine in dermatology: Part II
2010, Journal of the American Academy of DermatologyCitation Excerpt :Potassium-sparing diuretics should also be avoided, because cyclosporine can increase serum potassium. The increased risk of malignancy associated with long-term cyclosporine use in transplant populations is well described.104,105 In this population, however, multiple immunosuppressive agents are frequently used in concert, resulting in higher levels of immunosuppression.
Safety Profile of IBD: Lymphoma Risks
2010, Medical Clinics of North AmericaCitation Excerpt :As noted previously, the hypothesis that immunosuppression directly increases the risk of lymphoma is supported by observations of lymphoma regression with discontinuation of immunosuppression therapy. In the setting of organ transplantation and treatment of dermatologic disorders, complete remission of lymphomas associated with CsA treatment has occurred after dose reduction or discontinuation of the drug.50 MTX is a structural analogue of folic acid that inhibits the activity of dihydrofolate reductase, the enzyme responsible for converting folic acid to folate cofactors.
Safety Profile of IBD: Lymphoma Risks
2009, Gastroenterology Clinics of North AmericaCitation Excerpt :A worldwide study of more than 5000 organ transplant patients found that 0.5% of men (10 men in total) and fewer than 0.1% of women (1 female patient) developed lymphoma, with differing latency periods from time of drug therapy to malignancy diagnosis for different transplant indications.50 This translated into an approximately 28-times higher risk of lymphoma in patients treated with CsA.50 A 5-year prospective cohort study of 1252 patients with psoriasis treated with CsA found no trend toward an increased incidence of malignancies over time within the cohort.51
Treatments for psoriasis and the risk of malignancy
2009, Journal of the American Academy of DermatologyCitation Excerpt :CsA, a calcineurin inhibitor, blocks production of interleukin 2 by activated CD4-positive T cells, thereby hindering the inflammatory process central to psoriasis for which CsA has been effectively used for more than two decades.48-50 In transplant patients, long-term treatment with CsA is associated with serious side effects, including risk of lymphoma, internal malignancies, skin cancers, and infections.51-54 In 1992, Koo et al55 reported the first case in the United States of lymphoma in a patient treated with CsA for a condition other than organ transplantation.